Roche Inks Potential $1.8B Deal With Flare to Target Transcription Factors in Cancer
Roche on Tuesday entered into a back-heavy oncology deal with Flare Therapeutics, paying $70 million upfront to discover and advance new small molecule drug candidates against previously undruggable transcription factors to enhance or suppress the …